Perspective Therapeutics Inc
CATX
Market Cap$900.16M
Close$
$0.92
75.6% downside
Current Fair Value
75.6% downsideOvervalued by 75.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $900.16 Million |
|---|---|
| Enterprise Value | $844.04 Million |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $-0.1 |
| Beta | 1.44 |
| Outstanding Shares | 280,558,000 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -174.52 |
|---|---|
| PEG | -277.92 |
| Price to Sales | - |
| Price to Book Ratio | 3.76 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -10.2 |
| Enterprise Value to Net Income | -11 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.02 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Perspective Therapeutics Inc
64 employees
CEO: Lori Woods Isoray, Inc., through its subsidiary, Isoray Medical, Inc., is the sole producer of Cesium Blu brachytherapy seeds, which are expanding brachytherapy treatment options throughout the body.